FDA’s Remarkable ALS Drug Approval: Call It The 'Hendeles Standard'
Executive Summary
US FDA’s approval of Mitsubishi's Radicava (edaravone) is yet another demonstration of the agency’s flexibility for drugs to treat rare diseases – and pre-emptive action to fend off “Right to Try” laws. It is also a belated endorsement of one of the stranger votes by an FDA advisory committee member almost a decade ago.
You may also be interested in...
US FDA’s Foreign Data Policy Faces Its Greatest Test From Chinese PD-1/L1 Inhibitors
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.
ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS
Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.
Big Pharma May 2017: Product Developments Shift Stock
In a new monthly column, Scrip rounds up events on the stock market, noting trends and exceptional performance both good and bad. This month, the focus is on 30 biopharma companies with market caps above $10bn. Between them, these 30 companies account for approximately 75% of the asset value in the pharmaceutical industry.